1620 Investment Advisors, Inc. Biomarin Pharmaceutical Inc Transaction History
1620 Investment Advisors, Inc.
- $126 Million
- Q4 2024
A detailed history of 1620 Investment Advisors, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 1,434 shares of BMRN stock, worth $94,084. This represents 0.07% of its overall portfolio holdings.
Number of Shares
1,434
Previous 1,348
6.38%
Holding current value
$94,084
Previous $94,000
-0.0%
% of portfolio
0.07%
Previous 0.08%
Shares
3 transactions
Others Institutions Holding BMRN
# of Institutions
626Shares Held
183MCall Options Held
2MPut Options Held
1.67M-
Black Rock Inc. New York, NY22.7MShares$1.49 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.4MShares$1.27 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.2MShares$1.19 Billion0.94% of portfolio
-
Dodge & Cox San Francisco, CA14.7MShares$968 Million0.61% of portfolio
-
Capital Research Global Investors Los Angeles, CA13MShares$852 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.2B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...